Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
13(54%)
Results Posted
75%(6 trials)
Terminated
1(4%)

Phase Distribution

Ph early_phase_1
3
13%
Ph phase_1
2
8%
Ph phase_4
1
4%
Ph not_applicable
4
17%
Ph phase_2
11
46%
Ph phase_3
1
4%

Phase Distribution

5

Early Stage

11

Mid Stage

2

Late Stage

Phase Distribution22 total trials
Early Phase 1First-in-human
3(13.6%)
Phase 1Safety & dosage
2(9.1%)
Phase 2Efficacy & side effects
11(50.0%)
Phase 3Large-scale testing
1(4.5%)
Phase 4Post-market surveillance
1(4.5%)
N/ANon-phased studies
4(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

13

trials recruiting

Total Trials

24

all time

Status Distribution
Active(13)
Completed(8)
Terminated(1)
Other(2)

Detailed Status

Completed8
Active, not recruiting7
Recruiting6
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
24
Active
13
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (13.6%)
Phase 12 (9.1%)
Phase 211 (50.0%)
Phase 31 (4.5%)
Phase 41 (4.5%)
N/A4 (18.2%)

Trials by Status

active_not_recruiting729%
completed833%
recruiting625%
unknown28%
terminated14%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT05588128

Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL

Recruiting
NCT05616650Phase 2

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Recruiting
NCT03860987Phase 2

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Active Not Recruiting
NCT03976843Phase 2

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

Active Not Recruiting
NCT04687969

Multimodal Machine Learning Characterization of Solid Tumors

Active Not Recruiting
NCT03181867Phase 2

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Active Not Recruiting
NCT05155046Phase 2

18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

Recruiting
NCT03173924Phase 2

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

Active Not Recruiting
NCT03861676Early Phase 1

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

Recruiting
NCT04573231Phase 2

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Recruiting
NCT03535831Not Applicable

PSMA PET Registry (18F-DCFPyL)

Completed
NCT06099093Phase 4

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Recruiting
NCT03253744Phase 1

Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

Completed
NCT05095519Phase 2

Hepatocellular Carcinoma Imaging Using PSMA PET/CT

Active Not Recruiting
NCT03392181Early Phase 1

PET/MRI for the Staging of Newly Diagnosed Prostate Cancer

Active Not Recruiting
NCT04390880Phase 2

18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer

Completed
NCT04727736Phase 2

18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer

Terminated
NCT03811899Not Applicable

18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)

Completed
NCT03739684Phase 3

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

Completed
NCT02151760Phase 1

Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer

Completed

Drug Details

Intervention Type
DRUG
Total Trials
24